Esther Sanfeliu - Publications

SAFE-IOERT prospective study: clinical outcomes of exclusive intraoperative radiotherapy in early breast cancer according to molecular subtype and tumor-infiltrating lymphocytes.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: April 15, 2026

Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study.

Journal: ESMO real world data and digital oncology

Published: February 06, 2026

HER2DX genomic assay in HER2-positive early breast cancer treated with trastuzumab and pertuzumab: A correlative analysis from a real-world cohort.

Journal: Breast (Edinburgh, Scotland)

Published: January 12, 2026

Erratum to "Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study": [ESMO Open 9 (2024) 103989].

Journal: ESMO open

Published: January 06, 2026

The present and the future of antimicrobial resistance surveillance in Catalonia (Spain), 2024: from manual to automatic notification.

Journal: Antimicrobial resistance and infection control

Published: October 20, 2025

Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxane.

Journal: NPJ breast cancer

Published: September 15, 2025

Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 19, 2025

Palbociclib, Trastuzumab, and Endocrine Therapy in Pretreated HER2-Positive and PAM50 Luminal Advanced Breast Cancer: Randomized Phase II, SOLTI-1303 PATRICIA Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 05, 2025

Palbociclib, trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer: randomised phase II, SOLTI-1303 PATRICIA trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 05, 2025

Case Report: Personalized management of HER2-positive breast cancer with advanced nodal disease during pregnancy: a clinical case and review.

Journal: Frontiers in oncology

Published: July 24, 2025

Pembrolizumab and Paclitaxel in HR+/HER2- Breast Cancer with HER2-Enriched or Basal-Like Subtypes.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 11, 2025

Ki67 dynamic predicts endocrine sensitivity in estrogen receptor-positive/HER2-negative breast cancer patients undergoing preoperative endocrine therapy.

Journal: ESMO open

Published: July 11, 2025